

## Technology Advisory Committee B Interests Register

### Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]

Publication Date: 25/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Charles Crawley	Committee Chair	Direct - Non-financial professional and personal interest	He treats patients with Myeloma in his NHS practice.	19/12/2022	N/A	It was agreed that his declaration would not prevent Dr Charles Crawley from participating in discussions on this appraisal.
David McAllister	Committee Member	Indirect - Professional	He conducts academic research using individual-level participant data provided by the sponsors and/or their competitors. The data is accessed via trial data sharing platforms (such as Vivli).	09/01/2023	N/A	It was agreed that his declaration would not prevent Professor David McAllister from participating in discussions on this appraisal.
Peter Wheatley Price	Committee Member	Indirect - Financial interests	Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory	07/06/2023	N/A	It was agreed that his declaration would prevent Peter Wheatley Price from participating in discussions on this

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			multiple myeloma (TA505). The company has just successfully exited the CDF (ID1635). Although it is different line, the use of DRd in NDMM will direct impact the treatment pathway downstream.			appraisal and he did not attend.
Shelagh McKinlay	Patient expert	Indirect - Financial interest	Myeloma UK receives funding from Celgene, Bristol Myers-Squibb, and Janssen-Cilag for a range of purposes and activities namely core grants, project specific work including clinical trials, and gifts, honoraria or sponsorship.	21/12/2022	N/A	It was agreed that her declaration would not prevent Shelagh McKinlay from providing expert advice to the committee.
Gordon Cook	Clinical expert	Indirect Non-financial - professional and personal interest	He is a Myeloma specialist and has advised NHS England on BMT, CRG and chemotherapy CRG and the implementation of cartridges in myeloma. He also receives consultancy from BMS/Celgene, Takeda, Janssen, Sanofi, Roche,	16/05/2022	N/A	It was agreed that his declaration would not prevent Professor Gordon Cook from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Amgen, Oncopeptides, Karyopharm, Abbvie, Pfizer.			
Dr Neil Rabin	Clinical expert	Indirect - Financial interest	He has received funding from Janssen-Cilag, Celgene (BMS), Takeda, Sanofi, Karyopharm, and Amgen for various reasons which include attending conferences and speaking at educational meetings and advisory boards.	10/06/2022	N/A	It was agreed that his declaration would not prevent Dr Neil Rabin from providing expert advice to the committee.